Service interruption on Monday 11 July from 12:30 to 13:00: all the sites of the CCSD (HAL, EpiSciences, SciencesConf, AureHAL) will be inaccessible (network hardware connection).
Skip to Main content Skip to Navigation
Journal articles

Introduction to expert opinion on endocrine complications of new anticancer therapies

Abstract : Over the last 10 years, cancer treatment has progressed, with increasing use of tyrosine kinase inhibitors, mTOR inhibitors and, most recently, immunotherapy. These molecules, however, also incur side-effects, including endocrine toxicity. As their indications are constantly increasing, due to proven efficacy, it is important for endocrinologists to know how to monitor and manage such toxicity. The French Society of Endocrinology therefore drew up a consensus statement on these points. The present introductory text summarizes the main data on these molecules' action mechanisms and the epidemiology of the main endocrine side-effects. It will be followed up by sections on organ toxicity and a summary section on patients' overall survival. (C) 2018 Elsevier Masson SAS. All rights reserved.
Document type :
Journal articles
Complete list of metadata
Contributor : Valérie Gall Connect in order to contact the contributor
Submitted on : Wednesday, January 23, 2019 - 6:00:31 PM
Last modification on : Friday, March 25, 2022 - 2:02:09 PM


  • HAL Id : hal-01991343, version 1



Frederic Castinetti, Francoise Borson-Chazot. Introduction to expert opinion on endocrine complications of new anticancer therapies. Annales d'Endocrinologie, Elsevier Masson, 2018, 79 (5), pp.535-538. ⟨hal-01991343⟩



Record views